β1受体阻滞剂通过抑制TLR4/NF-ΚB信号通路减轻脓毒症成年大鼠心肌炎症
该研究将60只雄性Wistar大鼠随机分为4组(每组15只):假手术组、脓毒症模型组(盲肠结扎穿孔,CLP)、β1受体阻滞剂艾司洛尔干预组(ES组)和TLR4抑制剂E5564干预组。ES组经尾静脉微量泵注射艾司洛尔15 mg×kg-1×h-1,E5564组在CLP术前1小时经尾静脉微量泵注射E5564 0.3 mg×kg-1×h-1,S组、CLP组和E5564组皮下注射0.9%氯化钠2.0 mL/kg。造模后6小时采样,与CLP组相比,ES组和E5564组心脏指数(CI)显著升高、血清cTnI、IL-1β、TNF-α水平及心肌组织NF-ΚB p65、IL-1β、TNF-α蛋白表达显著降低,但TLR4蛋白表达无显著差异;ES组与E5564组间上述指标均无显著差异。作者认为艾司洛尔可能通过TLR4/NF-ΚB信号通路抑制脓毒症成年大鼠心肌炎症反应,从而减轻脓毒症诱导的心肌损伤。
要点
- 在脓毒症成年大鼠中,艾司洛尔组与E5564组心脏指数均高于CLP组(58.6±4.3、58.9±4.4 vs. 41.2±3.9 mL×s-1×m-2,均P<0.01)。
- 艾司洛尔组与E5564组血清cTnI、IL-1β、TNF-α均低于CLP组(均P<0.01),提示心肌损伤与炎症减轻。
- 艾司洛尔组与E5564组心肌组织NF-ΚB p65、IL-1β、TNF-α蛋白表达均低于CLP组(均P<0.01),但TLR4蛋白表达无显著差异(均P>0.05)。
- 艾司洛尔组与E5564组之间CI、血清cTnI、IL-1β、TNF-α及心肌组织TLR4、NF-ΚB p65、IL-1β、TNF-α蛋白表达均无显著差异(均P>0.05)。
- 各组平均动脉压无显著差异,提示上述变化并非由血压差异所致。
适用人群与场景
- 60只雄性Wistar大鼠,体重250-300 g,3月龄。
- 脓毒症模型采用盲肠结扎穿孔(CLP)建立;假手术组仅行切口。
处置流程与药物剂量
- 艾司洛尔组:经尾静脉微量泵注射艾司洛尔15 mg×kg-1×h-1。
- E5564组:CLP术前1小时经尾静脉微量泵注射E5564 0.3 mg×kg-1×h-1。
- 假手术组、CLP组和E5564组:皮下注射0.9%氯化钠2.0 mL/kg。
- 造模后6小时采集样本。
研究设计与关键结果
- 研究类型为动物实验;60只雄性Wistar大鼠随机分为4组(每组15只):假手术组(S组)、脓毒症模型组(CLP组)、艾司洛尔干预组(ES组)和TLR4抑制剂E5564干预组。
- 各组平均动脉压无显著差异。
- 与S组相比,CLP组CI显著降低,血清cTnI、IL-1β、TNF-α水平显著升高,心肌组织TLR4、NF-ΚB p65、IL-1β、TNF-α蛋白表达显著升高。
- 与CLP组相比,ES组和E5564组CI显著升高(58.6±4.3、58.9±4.4 vs. 41.2±3.9 mL×s-1×m-2,均P<0.01)。
- 与CLP组相比,ES组和E5564组血清cTnI、IL-1β、TNF-α显著降低(cTnI:1 113.81±26.64、1 115.74±25.90 vs. 1 975.96±42.74 μg/L;IL-1β:39.6±4.3、38.9±4.4 vs. 61.2±3.9 ng/L;TNF-α:43.1±2.8、48.7±2.6 vs. 81.3±4.4 ng/L,均P<0.01)。
- 与CLP组相比,ES组和E5564组心肌组织NF-ΚB p65、IL-1β、TNF-α蛋白表达显著降低(NF-ΚB p65/β-actin:0.31±0.03、0.43±0.04 vs. 0.85±0.08;IL-1β/β-actin:0.28±0.05、0.32±0.03 vs. 0.71±0.06;TNF-α/β-actin:0.18±0.04、0.28±0.03 vs. 0.78±0.07,均P<0.01),但TLR4蛋白表达无显著差异(TLR4/β-actin:0.89±0.07、0.87±0.09 vs. 0.95±0.09,均P>0.05)。
- ES组与E5564组之间CI、血清cTnI、IL-1β、TNF-α及心肌组织TLR4、NF-ΚB p65、IL-1β、TNF-α蛋白表达均无显著差异(均P>0.05)。
证据类型、等级与局限
- 证据类型:动物实验(大鼠)。
- 作者结论:β1受体阻滞剂艾司洛尔可能通过TLR4/NF-ΚB信号通路抑制脓毒症成年大鼠心肌炎症反应,从而减轻脓毒症诱导的心肌损伤。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该动物实验提示艾司洛尔可能通过TLR4/NF-ΚB信号通路减轻脓毒症相关心肌炎症和损伤,作者认为其可能成为减轻脓毒症诱导心肌损伤的干预方向。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore whether β1 receptor blocker could decrease the myocardial inflammation through the Toll-like receptor 4/nuclear factor-ΚB (TLR4/NF-ΚB) signaling pathway in the sepsis adult rats.
METHODS: Sixty male Wistar rats (250-300 g) aged 3 months old were allocated to four groups by random number table (n = 15): sham operation group (S group), sepsis model group (CLP group), β1 receptor blocker esmolol intervention group (ES group), and inhibitor of the TLR4 E5564 intervention group (E5564 group). The rat sepsis model was established by cecal ligation and puncture (CLP); S group of rats underwent only an incision. Rats in S group, CLP group and E5564 group were subcutaneous injected with 0.9% sodium chloride (NaCl) 2.0 mL/kg. Besides, the rats in ES group were injected with esmolol (15 mg×kg-1×h-1) by micro pump through the caudal vein. The rats in E5564 group were injected with E5564 (0.3 mg×kg-1×h-1) by micro pump through the caudal vein 1 hour before the CLP surgery. Samples were collected 6 hours after the modelling in each group. The average arterial pressure (MAP) and cardiac output index (CI) were monitored by PU electrical conduction ECG monitor. The levels of serum cardiac troponin I (cTnI), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) were detected by enzyme linked immunosorbent assay (ELISA). The expressions of TLR4, NF-ΚB p65, IL-1β, TNF-α in myocardial tissue was detected by Western Blot.
RESULTS: There was no significant difference in MAP in each group. Compared with the S group, the CI in the CLP group was significantly decreased, the levels of serum cTnI, IL-1β, TNF-α were significantly increased, the protein expressions of myocardial tissue TLR4, NF-ΚB p65, IL-1β and TNF-α were significantly increased. Compared with the CLP group, the CI in the ES group and E5564 group were significantly increased (mL×s-1×m-2: 58.6±4.3, 58.9±4.4 vs. 41.2±3.9, both P < 0.01), the levels of serum cTnI, IL-1β and TNF-α were significantly decreased [cTnI (μg/L): 1 113.81±26.64, 1 115.74±25.90 vs. 1 975.96±42.74; IL-1β (ng/L): 39.6±4.3, 38.9±4.4 vs. 61.2±3.9; TNF-α (ng/L): 43.1±2.8, 48.7±2.6 vs. 81.3±4.4, all P < 0.01], the protein expressions of myocardial tissue NF-ΚB p65, IL-1β, TNF-α were significantly decreased (NF-ΚB p65/β-actin: 0.31±0.03, 0.43±0.04 vs. 0.85±0.08; IL-1β/β-actin: 0.28±0.05, 0.32±0.03 vs. 0.71±0.06; TNF-α/β-actin: 0.18±0.04, 0.28±0.03 vs. 0.78±0.07, all P < 0.01), but there was no significant difference in protein expression of TLR4 (TLR4/β-actin: 0.89±0.07, 0.87±0.09 vs. 0.95±0.09, both P > 0.05). There was no significant difference in CI, the levels of serum cTnI, IL-1β, TNF-α, and the protein expressions of myocardial tissue TLR4, NF-ΚB p65, IL-1β, TNF-α between ES group and E5564 group (all P > 0.05).
CONCLUSIONS: β1 receptor blocker esmolol may inhibit myocardial inflammatory response in sepsis adult rats through TLR4/NF-ΚB signaling pathway, thereby alleviating sepsis-induced myocardial injury.
参考来源
- Liu X, Wen M, Li X, et al. [β1 receptor blocker decreases the myocardial inflammation in the sepsis adult rats through inhibition of TLR4/NF-ΚB signaling pathway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 30827308. doi:10.3760/cma.j.issn.2095-4352.2019.02.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。